Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Rohto PharmaceuticalLtd Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Rohto PharmaceuticalLtd yıllık ortalama 21.8% oranında kazançlarını artırırken, Personal Products sektöründe kazançlar growing at 5% annual. Gelirler growing yılda ortalama 9.3% oranında artmaktadır. Rohto PharmaceuticalLtd'in özkaynak karlılığı 11.9% ve net marjı 10.9%'dir.

Anahtar bilgiler

21.8%

Kazanç büyüme oranı

21.8%

EPS büyüme oranı

Personal Products Sektör Büyümesi	5.4%
Gelir büyüme oranı	9.3%
Özkaynak getirisi	11.9%
Net Marj	10.9%
Sonraki Kazanç Güncellemesi	13 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price

Oct 06

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Sep 22

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Aug 25

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Aug 11

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Jun 23

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Jun 10

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

May 14

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Mar 21

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Mar 07

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Feb 26

Gelir ve Gider Dağılımı

Rohto PharmaceuticalLtd nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

TSE:4527 Gelir, gider ve kazançlar (JPY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	278,025	30,328	104,519	13,390
31 Mar 24	270,840	30,936	101,306	13,390
31 Dec 23	263,564	30,897	99,527	11,065
30 Sep 23	256,220	29,779	97,054	11,065
30 Jun 23	247,580	28,473	93,411	11,065
31 Mar 23	238,664	26,377	90,479	11,065
31 Dec 22	231,887	25,722	89,098	8,740
30 Sep 22	218,940	23,454	84,262	8,740
30 Jun 22	209,586	23,281	80,344	8,740
31 Mar 22	199,646	21,018	77,460	8,740
31 Dec 21	195,698	22,593	76,636	7,903
30 Sep 21	189,302	21,321	76,272	7,903
30 Jun 21	184,961	19,537	75,019	7,903
31 Mar 21	181,287	16,743	75,147	7,903
31 Dec 20	179,819	13,931	77,997	7,050
30 Sep 20	180,903	14,283	78,052	7,050
30 Jun 20	185,058	15,130	80,840	7,050
31 Mar 20	188,327	15,410	82,733	7,050
31 Dec 19	187,006	11,490	82,321	6,831
30 Sep 19	186,751	9,787	82,548	6,831
30 Jun 19	184,854	8,576	82,192	6,831
31 Mar 19	183,582	9,799	80,602	6,831
31 Dec 18	182,328	10,058	80,189	6,553
30 Sep 18	180,503	10,959	78,752	6,553
30 Jun 18	176,543	10,454	76,177	6,553
31 Mar 18	171,742	9,289	74,106	6,553
31 Dec 17	167,286	11,699	72,440	6,123
30 Sep 17	161,799	11,467	69,929	6,123
30 Jun 17	157,557	10,913	68,783	6,123
31 Mar 17	154,599	10,011	68,414	6,123
31 Dec 16	158,115	9,705	69,538	5,811
30 Sep 16	160,973	8,416	73,002	5,811
30 Jun 16	164,467	9,143	74,140	5,811
31 Mar 16	167,016	9,098	76,241	5,811
31 Dec 15	164,639	10,591	75,746	5,585
30 Sep 15	161,852	9,926	74,709	5,585
30 Jun 15	157,167	9,311	72,317	5,585
31 Mar 15	151,774	8,631	70,551	5,585
31 Dec 14	148,167	6,608	69,423	4,547
30 Sep 14	146,495	8,002	66,855	4,547
30 Jun 14	143,900	7,676	65,396	4,547
31 Mar 14	143,822	8,947	63,717	4,547
31 Dec 13	139,613	9,183	61,343	4,062

Kaliteli Kazançlar: 4527 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 4527 'nin mevcut net kar marjları (10.9%) geçen yılın (11.5%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4527 şirketinin kazançları son 5 yılda yılda 21.8% oranında önemli ölçüde arttı.

Büyüme Hızlandırma: 4527 'un son bir yıldaki kazanç büyümesi ( 6.5% ) 5 yıllık ortalamasının ( 21.8% /yıl) altındadır.

Kazançlar vs. Sektör: 4527 geçen yılki kazanç büyümesi ( 6.5% ) Personal Products sektörünün -1.7% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 4527 'nin Özsermaye Getirisi ( 11.9% ) düşük olarak değerlendiriliyor.

Rohto PharmaceuticalLtd Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024

Third quarter 2024 earnings released: EPS: JP¥41.92 (vs JP¥37.02 in 3Q 2023)

Recent updates

Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price

Now 21% undervalued

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Upcoming dividend of JP¥16.00 per share

Now 20% undervalued

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Second Quarter-End and Full Fiscal Year Ending March 31, 2025

Investor sentiment deteriorates as stock falls 16%

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Final dividend of JP¥15.00 announced

Now 20% undervalued

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million.

Now 21% undervalued after recent price drop

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Upcoming dividend of JP¥15.00 per share

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Now 21% undervalued after recent price drop

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Third quarter 2024 earnings released: EPS: JP¥41.92 (vs JP¥37.02 in 3Q 2023)

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024

Price target decreased by 7.5% to JP¥3,814

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023

Price target increased by 9.4% to JP¥4,126

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Upcoming dividend of JP¥12.00 per share at 0.6% yield

Price target increased by 9.4% to JP¥3,999

Price target increased by 9.0% to JP¥3,884

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Price target decreased by 13% to JP¥3,206

Full year 2023 earnings: EPS exceeds analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Price target increased by 27% to JP¥3,531

Price target increased by 8.4% to JP¥2,870

Upcoming dividend of JP¥12.00 per share at 0.9% yield

Rohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥20.00 per share

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2023 Results on Aug 09, 2022

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2022